OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Badami on Factors Informing Treatment Selection in ccRCC and Non–ccRCC

November 8th 2024

Ami Umesh Badami, MD, discusses the factors that guide treatment decision-making for patients with clear cell or non–clear cell renal cell carcinoma.

Dr Thaker on the Role of the Glucocorticoid Pathway in Platinum-Resistant Ovarian Cancer

November 8th 2024

Premal Thaker, MD, MS, discusses the role of the glucocorticoid receptor pathway and the development of chemoresistance in ovarian cancer.

Dr Lee on the Surgical Implications of Molecular Testing in NSCLC

November 8th 2024

Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.

Dr Shore on the Rationale for the Duravelo-2 Trial in Metastatic Urothelial Cancer

November 8th 2024

Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.

Dr Feldman on the Recognition of Racial Disparities in Breast Cancer

November 7th 2024

Sheldon M. Feldman, MD, discusses the recognition of racial disparities in breast cancer, as well as the mitigation of treatment-related toxicities.

Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPC

November 7th 2024

Louis Crain Garrot, MD, discusses the role of lutetium Lu 177 in older patients with metastatic castration-resistant prostate cancer.

Dr Delforge on the Rationale for CARTITUDE-4 in Lenalidomide-Refractory Myeloma

November 7th 2024

Michel Delforge, MD, PhD, discusses the rationale for conducting the CARTITUDE-4 trial investigating cilta-cel in lenalidomide-refractory multiple myeloma.

Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma

November 7th 2024

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.

Dr Parikh on Available Treatment Options for HER2+ CRC

November 7th 2024

Aparna Parikh, MD, discusses currently available treatment options for patients with HER2-positive colorectal cancer.

42nd Annual CFS Preview for Medical Oncologists: The Show and After Show

November 7th 2024

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

Dr Sharma on Key Trials Within the Urothelial Cancer Therapeutic Paradigm

November 7th 2024

Janaki Neela Sharma, MD, discusses which trials have shifted the therapeutic paradigm for patients with urothelial cancer.

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

November 7th 2024

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Dr Ashraf on the Utility of T-DXd in HER2-Mutated NSCLC

November 7th 2024

Noman Ashraf, MD, discusses notable data seen with T-DXd treatment in previously treated HER2-mutated and -overexpressing non–small cell lung cancer.

Dr Feldman on the Significance of the HER2-Low Classification in HER2+ Breast Cancer

November 7th 2024

Sheldon M. Feldman, MD, discusses the significance of the new classification of HER2-low breast cancer and how this affects HER2+ breast cancer treatment

Dr Bardia on Findings From DESTINY-Breast06 in HER2-Low Breast Cancer

November 6th 2024

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

Dr Baik on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLC

November 6th 2024

Christina S. Baik, MD, MPH, discusses the clinical utility of zongertinib in previously treated non–small cell lung cancer harboring HER2 TKD mutations.

Dr Zakalik on the Role of Genetic Testing to Guide Breast Cancer Treatment

November 6th 2024

Dana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.

Dr Fisher on Mechanisms of Resistance to Pirtobrutinib in CLL

November 6th 2024

David C. Fisher, MD, discusses pirtobrutinib resistance mechanisms that may develop during therapy in patients with CLL

Dr Kalinsky on the Future of Treatment With T-DXd in HER2+ Breast Cancer

November 5th 2024

Kevin Kalinsky, MD, MS, discusses future treatment directions with T-DXd in breast cancer, as well as the evolving role of HER2 classification.

Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors

November 5th 2024

Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.